<DOC>
	<DOC>NCT02227784</DOC>
	<brief_summary>The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.</brief_summary>
	<brief_title>A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Must be treated with atorvastatin 40 mg/day for at least 30 days prior to screening Have an LDLC &gt;70 mg/deciliter(dL) or nonHDLC &gt;100 mg/dL Have screening triglycerides ≤400 mg/dL (≤4.5 millimoles/Liter) Individuals with ASCVD and/or individuals with type 1 or type 2 diabetes Have a hemoglobin A1c (HbA1c) &gt;9.5% New York Heart Association (NYHA) class III or IV congestive heart failure History of either a transient ischemic stroke or ischemic stroke &lt;30 days History of acute coronary syndrome (ACS) &lt;30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>